Abstract：Objective To study the dynamic changes in the percentage of Th17 cells/CD4+CD25+ regulatory T cells after intervention with montelukast sodium, a leukotriene receptor antagonist, in asthmatic mice and the association between them. Methods Balb/c mice were randomly divided into blank group, asthma group, and montelukast sodium group. The asthmatic mouse model of airway remodeling was established by sensitization with intraperitoneal injection of chicken ovalbumin (OVA) and aluminum hydroxide suspension and aerosol inhalation of OVA. The mice in the blank group were given normal saline, and those in the montelukast sodium group were given montelukast sodium by gavage before aerosol inhalation. Eight mice were randomly sacrificed within 24 hours after 2, 4, and 8 weeks of aerosol inhalation. The pathological sections of lung tissue were used to observe the degree of airway remodeling. Flow cytometry was used to measure the percentages of Th17 cells and CD4+CD25+ regulatory T cells in CD4+ T cells. Results The asthma group and the montelukast sodium group had significantly higher bronchial wall thickness and smooth muscle thickness at all time points compared with the blank group (P < 0.05). At 8 weeks of intervention, the montelukast sodium group had significantly greater improvements in the above changes compared with the asthma group (P < 0.05). Compared with the blank group, the asthma group and the montelukast sodium group had significant increases in Th17 cells (positively correlated with airway remodeling) and significant reductions in CD4+CD25+ regulatory T cells (negatively correlated to airway remodeling) at all time points (P < 0.05). At 8 weeks of intervention, the montelukast sodium group had a significant reduction in the number of Th17 cells and a significant increase in the number of CD4+CD25+ regulatory T cells compared with the asthma group (P < 0.05). Conclusions Montelukast sodium intervention can alleviate airway remodeling and achieve better improvements over the time of intervention. The possible mechanism may be related to the improvement of immunologic derangement of CD4+CD25+ regulatory T cells and inhibition of airway inflammation.
LI Li,LOU Chun-Yan,LI Min et al. Effect of montelukast sodium intervention on airway remodeling and percentage of Th17 cells/CD4+CD25+ regulatory T cells in asthmatic mice[J]. CJCP, 2016, 18(11): 1174-1180.
Segura V,Pérez-Aso M,MontóF,et al.Differences in the signaling pathways of α(1A)-and α(1B)-adrenoceptors are related to different endosomal targeting[J].PLoS One,2013,8(5):e64996.
[3]
Kearley J,Robinson DS,Lloyd CM.CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling[J].J Allergy Clin Immunol,2008,122(3):617-624.
[4]
Poulin S,Thompson C,Thivierge M,et al.Cysteinylleukotrienes induce vascular endothelial growth factor production in human monocytes and bronchial smooth muscle cells[J].Clin Exp Allergy,2011,41(2):204-217.
Temelkovski J,Hogan SP,Shepherd DP,et al.An improved murine model of asthma:selective airway inflammation,epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen[J].Thorax,1998,53(10):849-856.
Brembilla NC,Montanari E,Truchetet ME,et al.Th17 cells favor inflammatory responses while inhibiting type 1 collagen deposition by dermal fibroblasts:differential effects in healthy and systemic sclerosis fibroblasts[J].Arthritis Res Ther,2013,15(5):R151.
[10]
Wilson MS,Wynn TA.Pulmonary fibrosis:pathogenesis,etiology and regulation[J].Mucosal Immunol,2009,2(2):103-121.
[11]
Makinde T,Murphy RF,Agrawal DK.The regulatory role of TGF-beta in airway remodeling in asthma[J].Immunol Cell Biol,2007,85(5):348-356.
[12]
Diamant Z,Mantzouranis E,Bjermer L.Montelukast in the treatment of asthma and beyond[J].Expert Rev Clin Immunol,2009,5(6):639-658.
[13]
Global Initiative for Asthma.Global strategy for asthma management and prevention[EB/OL].(2015-05-19)[2016-04-29].
[14]
Singh RK,Tandon R,Dastidar SG,et al.A review on leukotrienes and their receptors with reference to asthma[J].J Ashma,2013,50(9):922-931.
[15]
Shin IS,Jeon WY,Shin HK,et al.Effects of montelukast on subepithelial/peribronchial fibrosis in a murine model of ovalbumin induced chronic asthma[J].Int Immunopharmacol,2013,17(3):867-873.
[16]
Souza FC,Gobbato NB,Maciel RG,et al.Effects of corticosteroid,montelukast and iNOS inhibition on distal lung with chronic inflammation[J].Respir Physiol Neurobiol,2013,185(2):435-445.
[17]
Yamakawa Y,Ohtsuka Y,Ohtani K,et al.Effects of leukotriene receptor antagonists on peripheral eosinophil counts and serum IgE levels in children with food allergy[J].Drugs R D,2010,10(3):147-154.
[18]
Han J,Jia Y,Takeda K,et al.Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus[J].Am J Respir Crit Care Med,2010,182(4):455-463.
Yüksel B,Aydemir C,Ustündag G,et al.The effect of treatment with montelukast on levels of serum interleukin-10,eosinophil cationic protein,blood eosinophil counts,and clinical parameters in children with asthma[J].Turk J Pediatr,2009,51(5):460-465.
